PER-064-21招募中3 期
A Phase 3, Multicenter, Randomized, Partially Blinded, Palivizumab-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of MK-1654 in Infants and Children at Increased Risk for Severe RSV Disease
Merck Sharp & Dohme LLC., (una subsidiaria de Merck & Co. Inc.)0 个研究点目标入组 20 人开始时间: 2022年12月28日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Recommended to receive palivizumab and meets 1 or more of the following criteria:
- •a)Early or Moderate Pre-term Group: =35 weeks, 0 days gestational age
- •b)CLD/CHD Group:
- •Participants that have CLD of prematurity (also known as bronchopulmonary Dysplasia)
- •Participants that have hemodynamically significant CHD.
- •Is available to complete the follow-up period:
- •Up to 575 days (180 days after RSV Season 2 dose) for participants eligible for RSV Season 2 dose of MK-1654, or
- •Approximately 365 days after the RSV Season 1 Dose 1 for all other participants.
- •Is male or female and has a chronological age from birth up to 1 year and is entering their first RSV season at the time informed consent is provided.
- •The participant’s legally acceptable representative provides documented informed consent for the study. The participant’s legally acceptable representative may also provide documented consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research.
- •Additional Inclusion criteria for participation in RSV season 2: Participants enrolled in the CLD/CHD group as defined in Inclusion Criteria #1b.
- •Participants with CHD are required to meet the following additional criteria:
- •Have hemodynamically significant CHD at the beginning of RSV Season 2, or
- •If the participant has had surgically repaired hemodynamically significant CHD that did not include ECMO or cardiopulmonary bypass:
- •Continues to require medications to manage CHD, or
- •Any additional medical intervention related to their CHD
- •Additional Inclusion criteria for participation in RSV season 2: Participants enrolled in the Early or Moderate Pre-term Group as defined in Inclusion Criteria #1a, with the following conditions:
- •Neuromuscular disease or congenital pulmonary anomaly that impairs the ability to clear secretions from the upper airway because of ineffective cough
- •Down Syndrome (trisomy of chromosome 21)
- •Cystic fibrosis with nutritional compromise (eg, weight <10th percentile at time of enrollment)
- •Native American
排除标准
- •Has known hypersensitivity to any component of MK-1654 (refer to the IB for a list of components) or palivizumab (refer to the Synagis® label for a list of components).
- •Has received other investigational agents at any time before study entry.
- •Has a prior surgical correction of CHD or anticipated cardiac surgical procedure within
- •60 days of randomization resulting in hemodynamically insignificant CHD.
- •Requires ECMO or continuous positive airway pressure at the time of enrollment.
- •Has an anticipated or planned cardiac transplantation to occur during the course of this study.
- •Has a bleeding disorder contraindicating intramuscular administration.
- •Has had a recent illness with rectal temperature =100.5°F (=38.1°C) or axillary
- •temperature =100.0°F (=37.8°C) within 72 hours predose.
- •Has symptoms of LRI (defined in Section 8.2.1) within 7 days predose.
- •Has received any vaccine or mAb for the prevention of RSV, including receipt of maternal RSV vaccination during the mother’s pregnancy.
- •Is currently participating in or has participated in an interventional clinical study with an investigational compound or device at any time before first dose administration or while participating in this current study. Participants enrolled in observational studies may be included and will be reviewed on a case-by-case basis for approval by the Sponsor.
- •Has enrolled previously in the current study and been discontinued.
- •Has a parent/legal guardian/legally acceptable representative who is unlikely to adhere to study procedures, keep appointments, or is planning to relocate during the study.
- •Has any other reason that in the opinion of the investigator may interfere with the evaluation required by the study.
- •Is or has an immediate family member (eg, spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.
- •Exclusion criteria for participation in RSV season 2: Has a life expectancy <6 months.
- •Exclusion criteria for participation in RSV season 2: Has known hepatic or renal dysfunction, or chronic seizure disorder.
- •Exclusion criteria for participati
研究者
相似试验
进行中（未招募）
1 期
Palivizumab-Controlled Evaluation of Safety, Efficacy, and Pharmacokinetics of MK-1654 in Infants and Children at Increased Risk for Severe RSV DiseasePrevention of Respiratory syncytial virus (RSV) infection in infants and children at increased risk for severe RSV diseaseMedDRA version: 21.1Level: LLTClassification code 10066742Term: Respiratory syncytial virus infection prophylaxisSystem Organ Class: 100000004865EUCTR2020-005996-11-CZMerck Sharp & Dohme LLC1,000
进行中（未招募）
1 期
Palivizumab-Controlled Evaluation of Safety, Efficacy, and Pharmacokinetics of MK-1654 in Infants and Children at Increased Risk for Severe RSV DiseaseEUCTR2020-005996-11-ESMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.1,000
进行中（未招募）
1 期
Palivizumab-Controlled Evaluation of Safety, Efficacy, and Pharmacokinetics of MK-1654 in Infants and Children at Increased Risk for Severe RSV DiseasePrevention of Respiratory syncytial virus (RSV) infection in infants and children at increased risk for severe RSV diseaseMedDRA version: 21.1Level: LLTClassification code 10066742Term: Respiratory syncytial virus infection prophylaxisSystem Organ Class: 100000004865EUCTR2020-005996-11-NOMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.1,000
进行中（未招募）
1 期
Palivizumab-Controlled Evaluation of Safety, Efficacy, and Pharmacokinetics of MK-1654 in Infants and Children at Increased Risk for Severe RSV DiseasePrevention of Respiratory syncytial virus (RSV) infection in infants and children at increased risk for severe RSV diseaseMedDRA version: 21.1Level: LLTClassification code: 10066742Term: Respiratory syncytial virus infection prophylaxis Class: 10042613CTIS2022-500752-39-00Merck Sharp & Dohme LLC936
进行中（未招募）
1 期
Palivizumab-Controlled Evaluation of Safety, Efficacy, and Pharmacokinetics of MK-1654 in Infants and Children at Increased Risk for Severe RSV DiseasePrevention of Respiratory syncytial virus (RSV) infection in infants and children at increased risk for severe RSV diseaseMedDRA version: 21.1Level: LLTClassification code 10066742Term: Respiratory syncytial virus infection prophylaxisSystem Organ Class: 100000004865EUCTR2020-005996-11-GRMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.1,000